Recursion Pharmaceuticals Reports Q3 Revenue Beat Amid GAAP EPS Miss
Recursion Pharmaceuticals (RXRX) reported third-quarter financial results characterized by significant year-over-year revenue growth alongside a slight miss on earnings per share. The company posted revenue of $18.55 million, representing a 258.1% increase compared to the previous year and exceeding analyst expectations by $3.74 million. Despite the top-line beat, GAAP earnings per share (EPS) came in at -$0.22, missing consensus estimates by $0.01. The company's performance comes amid broader strategic developments, including a recent $200 million equity offering and ongoing collaborations with partners like Sanofi.
